BioCentury | Jun 27, 2016
Clinical News

Fate Therapeutics preclinical data

...In pre-hyperglycemic non-obese diabetic mice, a single dose of ToleraCyte significantly delayed the median time to...
...American Diabetes Association meeting in New Orleans. Fate Therapeutics Inc. (NASDAQ:FATE), San Diego, Calif. Product: ToleraCyte...
Items per page:
1 - 1 of 1